We are delighted to let you know that our new research topic « Modulating Cytokines as Treatment for Autoimmune Diseases and Cancer: Volume II » is now open for submission at the « Cytokines and Soluble Mediators in Immunity » section of Frontiers in Immunology!

Topic Editors: Gaby Palmer (University of Geneva, Switzerland), Sheela Ramanathan (University of Sherbrooke, Canada) and Erwan Mortier (Nantes University, CNRS, Inserm, France)

The Research Topic web page can be found here.

If you are in the scope, please feel free to submit your work (Articles, Review)!

Brivéla is a Master 2 student from the University of Toulouse. She is going to work on understanding the dynamic of the formation of the IL-15 receptor. Welcome to our Lab!

SOTIO Announces Clinical Collaboration with MSD to evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

• The Phase 2 AURELIO-04 study is expected to enroll up to 300 patients across six different indications
• The study will be conducted in the US and selected European countries and will begin in the first half of 2022

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it has entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., through its subsidiaries, to evaluate the combination of SOT101, SOTIO’s IL-15 superagonist, and MSD’s KEYTRUDA® (pembrolizumab) in patients with selected advanced/refractory solid tumors in the phase 2 AURELIO-04 study.

December 8, 2021
Source: Press Release, Basel

SOT101 Shows Clinical Benefit in Patients with Advanced Solid Tumors

• Majority of patients receiving SOT101 (SO-C101) + pembrolizumab had confirmed clinical benefit
• Clinical responses have been observed in patients progressing on previous anti-PD-1 treatment
• SOT101 monotherapy and in combination with pembrolizumab was well tolerated in patients with advanced/metastatic solid tumors

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced new data from the ongoing Phase 1/1b AURELIO-03 study of SOT101, an IL-15 superagonist, as a monotherapy and in combination with pembrolizumab in patients with advanced/metastatic solid tumors.

November 12, 2021
Source: Press Release, Basel

New article from the Mocka lab, published in Bioorganic & Medicinal Chemistry by Smadja et al., in collaboration with the CEISAM Lab from Nantes.

see publication

Emeline (left) joins the Mocka Lab for her Msc. 2 training and Manon (right) for her Msc.1 training. Welcome!!